+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
A

Actively Recruiting

Researchers are conducting a Phase 3 pediatric clinical trial to study chronic weight management in children and adolescents aged 6 to 17 years who have obesity or are overweight with related health conditions. The study aims to create a master framework that evaluates the safety and effectiveness of medications for these participants. This trial is part of a broader platform trial design with multiple intervention sub-studies ISAs that may start independently as treatments become available. Participants will receive either the study drug orforglipron or a placebo orally, with each intervention sub-study detailing specific treatments. The master protocol sets common entry criteria for all participants across the different sub-studies. Results from the trial will be reported when all intervention sub-studies are completed. During the trial, participants will be monitored from baseline through 72 weeks, with assessments of how many are allocated to each intervention sub-study. Safety and efficacy will be evaluated through ongoing observation and data collection throughout the study period. The trial spans from screening through long-term follow-up, ensuring comprehensive evaluation of the treatments over time.

Age: 6Years - 17YearsAll GendersPhase 3
117 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.

Age: 18Years - 74YearsAll GendersPhase 2
139 locations
A

Actively Recruiting

Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
248 locations
S

Actively Recruiting

Researchers are studying the effects of tirzepatide added to healthy lifestyle changes in children aged 6 to under 12 years who have obesity. This phase 3 trial aims to evaluate how well tirzepatide works, its safety, and how the body processes the drug in this age group. Participants must have obesity defined by a body mass index BMI at or above the 95th percentile for their age and sex and have a history of at least one unsuccessful attempt to lose weight through structured diet and exercise. Participants are randomly assigned to receive either tirzepatide or a placebo, both given as weekly subcutaneous injections. The main treatment period lasts about 104 weeks, during which participants also continue lifestyle interventions. Those who complete this primary phase may have the option to continue receiving tirzepatide treatment for an additional 156 weeks while maintaining lifestyle changes. During the study, participants attend regular visits for assessments including measurements of BMI, body weight, waist circumference, blood pressure, cholesterol, glucose, insulin, liver enzymes, and quality of life questionnaires. Safety monitoring includes evaluating potential side effects and drug levels in the body. Overall participation can last up to about 260 weeks, combining the main treatment and extension periods.

Age: 6Years - 11YearsAll GendersPhase 3
82 locations
E

Actively Recruiting

Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.

Age: 18Years +All GendersPhase 3
162 locations
E

Actively Recruiting

Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.

Age: 12Years +All GendersPhase 3
478 locations